Bumetanide nasal spray for the treatment of edema in heart failure, liver disease and kidney disease: a narrative review
Year: 2026
Type: review
Abstract: Edema is a common manifestation of heart failure, advanced liver disease, and chronic kidney disease, reflecting an imbalance between sodium and water homeostasis that frequently requires treatment with loop diuretics. Despite their efficacy, oral formulations may be affected by variable gastrointestinal absorption, and delayed onset of action, whereas intravenous formulations require healthcare-based delivery. These challenges have stimulated interest in alternative drug delivery strategies able to provide a rapid, and predictable diuretic therapy. Intranasal bumetanide has emerged as a novel formulation designed to overcome these limitations by enabling systemic absorption through the highly vascularized nasal mucosa while bypassing the gastrointestinal tract. Early pharmacokinetic and pharmacodynamic studies in healthy volunteers show that intranasal bumetanide achieves rapid and consistent systemic exposure, with diuretic and natriuretic effects comparable to conventional diuretic formulations and acceptable short-term tolerability. However, direct clinical efficacy of intranasal bumetanide in patients with edema has not yet been prospectively established, and several questions regarding its optimal clinical management, long-term effectiveness, and cost-effectiveness are yet to be addressed. This narrative review aims to discuss the pharmacological characteristics, clinical efficacy, safety, and tolerability of bumetanide nasal spray, with emphasis on its use in patients with edema secondary to cardiac, hepatic, and renal disorders.
Source: Therapeutic Delivery
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225259082
